HC Wainwright Reaffirms “Buy” Rating for Oncolytics Biotech (NASDAQ:ONCY)

HC Wainwright reissued their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Oncolytics Biotech Trading Down 3.0 %

Oncolytics Biotech stock opened at $0.98 on Thursday. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75. The firm has a market capitalization of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. The firm’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.05.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent quarter. 6.82% of the stock is currently owned by institutional investors.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.